Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
How did MoneyWorks4me help subscribers to buy Persistent Systems at Rs. 700/ share in Jan 2020?
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Wanbury Ltd Stock Analysis

Small Cap
Evaluated by 321 users | BSE: 524212 | NSE: WANBURY |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Sep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Capital Employed 0.93%-0.75%-0.88%-17.03%5.49%7.44%46.91%-11.09%5.96%61.24%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 315345414441500423434371391367453
Y-o-Y Gr. Rt.-9.3%20.2%6.5%13.3%-15.3%2.5%-14.5%5.5%-6.1%-
Adjusted EPS (Rs.) -16.31-15.45-15.22-32.64-1.11-3.2924.89-13.87-10.382.46-0.71
Y-o-Y Gr. Rt.-NANANANANANA-155.7%NANA-
Book Value per Share (Rs.) 70.2852.2539.92-64.07-192.95-99.34-54.91-67.15-77.49-47.23-25.10
Adjusted Net Profit -24-26.9-26.5-65.2-2.2-6.657.8-32.9-24.66.1-2
Net Op. Cash Flow (Rs. Cr.) 28.3-40.518.249.180.143.243.432.529.744.1-
Debt to Cash Flow from Ops 11.79-9.7522.765.279.518.656.226.787.843.71-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Wanbury Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 1.7%-6%-5.4%-6.1%
Adjusted EPS NANA-53.8%NA
Book Value per Share -195.7000
Share Price 12.4% 8.2% 51.9% 113.3%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Sep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Equity (%) -14.09-18.17-20.78376.50.663.97-39.7822.9614.37-4.071.96
Operating Profit Margin (%) 4.062.343.916.888.587.924.27-18.233.57-5.886.07
Net Profit Margin (%) -7.6-7.79-6.39-14.77-0.44-1.5513.32-8.86-6.291.67-0.51
Debt to Equity 3.234.355.98-2.02-1.98-1.88-2.12-1.38-1.27-1.39-
Working Capital Days 3103152821472951621591277486-
Cash Conversion Cycle 41444621152-17-51-59-81-
Loading price chart...
Entity Percentage Holding
Promoters 39.90%
Institutions 0.01%
Non-Institutions 60.09%
Pledged *76.7676.7676.7676.7676.7676.7676.7676.7676.7676.76
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Wanbury Ltd's earnings have grown by 0%, whereas share price has appreciated 8.2% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Wanbury Ltd share price has appreciated 12.4% annually (CAGR) over the past ten years.

Data is not available for this company.

Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.

Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanbury’s major thrust area also lies in Active

Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.

Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanbury’s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.

The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets.

Product range of the company includes:

  • Coriminic table
  • Cpink table
  • Nock 2 tab
  • Senasof tab
  • Zevanuron
  • Rabiplus cap
  • Folinine
  • Cpink-s
  • Nuture
  • Adtrol 200mg

Milestones:

2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2007Doctor’s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the world’s largest producer of Metformin with production of 4500 MT.

2005Wanbury acquired Doctor’s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product API’s.

2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system.

2002Pearl Organics got US FDA approval for Patalganga plant.

1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US.

1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra).

1992Pearl Organics established its first plant in Tarapur for manufacturing API’s.

1991Pearl Distributors Pvt went public and was renamed as Pearl Organics.

1990Incorporated as Pearl Distributors Pvt

Achievements/ recognition:-

  • Wanbury ranks 47th as per ORG-IMS (Jan-2009) 
  • Cpink awarded “Best Brand Launch' by ORG IMS (06-07)  
  • Rabiplus awarded “Best Brand Launch' by ORG IMS (07-08) 
  • World's largest producer of Metformin
  • Fastest growing company amongst top 100 companies in the domestic market as per ORG IMS.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback